The Influence of Domain Permutations of an Albumin-Binding Domain-Fused HER2-Targeting Affibody-Based Drug Conjugate on Tumor Cell Proliferation and Therapy Efficacy

The Influence of Domain Permutations of an Albumin-Binding Domain-Fused HER2-Targeting Affibody-Based Drug Conjugate on Tumor Cell Proliferation and Therapy Efficacy

Human epidermal growth factor receptor 2 (HER2) is a clinically validated target for breast cancer therapy. Previously, a drug-fused HER2-targeting affinity protein construct successfully extended the survival of mice bearing HER2-expressing xenografts. The aim of this study was to evaluate the infl...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Wen Yin, Tianqi Xu, Mohamed Altai, Maryam Oroujeni, Jie Zhang, Anzhelika Vorobyeva, Olga Vorontsova, Sergey V. Vtorushin, Vladimir Tolmachev, Torbjörn Gräslund, Anna Orlova
Formato: article
Lenguaje:EN
Publicado: MDPI AG 2021
Materias:
HER2
affibody molecule
albumin-binding domain
drug conjugate
targeted therapy
mertansine
Pharmacy and materia medica
RS1-441
Acceso en línea:https://doaj.org/article/eb6ec5f0a85e41e9b8d153269cb79fda
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Internet

https://doaj.org/article/eb6ec5f0a85e41e9b8d153269cb79fda

Ejemplares similares